Overview on sporadic and NF-related tumors -- Natural history and clinical evolution of PNST in neurofibromatosi -- Advancement in genetic and molecular landscapes -- Multi-omic analyses for biomarker discovery and characterization of PNST -- Preclinical NF1-PNST models and potential drug resistance mechanism -- MRI in the diagnosis of PNST: state-of-the-art and recent advancements -- Developing the role of molecular imaging PET in PNST -- A clinical summary of PNST in adults -- Clinical assessment of tumor predisposition syndromes - related nerve sheath tumors in children -- IOUS and CEUS in PNS tumor -- Neurophysiological evaluation and intraoperative neurophysiology monitoring in peripheral nervous system tumor -- Surgical management of peripheral nerve sheath tumors -- Surgical Management of Pediatric PNS -- Fluorescent-guided surgery of PNST -- Esoscope in PNS tumors surgery -- Preserving nerve function and reconstruction in MPNS tumors -- New oral chemotherapy and MEK inhibitor (and other treatments for benign PNST) -- Systemic treatment in malignant peripheral nerve sheath tumors: current practice and future possibilities -- Proton and carbon ion therapy for MPNST -- Radiomics and machine learning in PNST.

This book offers an update about peripheral nerve sheath tumors (PNST), both in their benign and malignant forms (MPNST). Starting from the most innovative preclinical studies about genetic and omics characterization, it then explores the traditional and advanced imaging modalities (ultrasound, DTI, etc) and the electrophysiological assessment. Another relevant part is reserved to the description of the most recent surgical techniques (fluorescent dye for intraoperative surgical guidance, neurophysiological monitoring, esoscopic view). Finally, new oral treatment for PNST related to neurocutaneous diseases (as selumetinib in plexiform neurofibromas) is described. Written by worldwide experts in each specifical field, if offers a multidisciplinary vision to PNST, approaching the topic in a translational way, from preclinical studies to the current medical practice. The ideal readers are all health operators involved in the treatment of these tumors- from neurosurgeons to radiologists, neurologists, geneticists, biologists, etc) as well as medical students in these disciplines.